Dopamine receptor d1 agonists and methods of use

A compound having the structure of Formula (I), or a pharmaceutically acceptable salt or solvate thereof:

• wherein:
• X2 is N or CR5;
• X3 is N or CR6;
• X4 is CR7;
• m is 0, 1, or 2;
• R1 is halogen, —OH, —ORa, or C1-C6 alkyl;
• R2 is —OH, —ORa, or C1-C6 alkyl,
• R3 is halogen, —CN, —OH, —ORa, or C1-C6 alkyl;
• R4 is hydrogen or C1-C6 alkyl;
• i) R5 is hydrogen, halogen, —CN, —OH, —ORa, or C1-C6 alkyl;
• R6 is —OH, or —ORa;
• and
• R7 is —OH, or —ORa, or
• ii) R5 is —OH, or —ORa;
• R6 is —OH, or —ORa;
• and
• R7 is hydrogen, halogen, —CN, —OH, —ORa, or C1-C6 alkyl;
• and
• each Ra is independently C1-C6 alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —C1-C6 alkyl(aryl), —C1-C6 alkyl(heteroaryl), —C1-C6 alkyl(cycloalkyl), or —C1-C6 alkyl(heterocycloalkyl);
• wherein each C1-C6 alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently unsubstituted or substituted with one, two, or three halogen, —OH, C1-C6 alkyl, or C1-C6 haloalkyl.